<DOC>
	<DOCNO>NCT02404025</DOCNO>
	<brief_summary>This open label , non-randomized , phase II study eltrombopag combination rabbit ATG/CsA subject moderate severe AA receive prior ATG/ALG-based immunosuppressive therapy . The objective ass additive effect eltorombopag overall response rate ( ORR ) 6 month ( Week 26 ) treatment ATG/CsA . Subjects assess least weekly safety period start ATG/CsA 4 week start administration eltrombopag . After , subject visit every 2 week Week 26 . Subjects treatment assess effective Week 26 may continue treatment eltrombopag 6 month clinically indicate discretion investigator . There five follow-up visit : discontinuation treatment eltrombopag , Weeks 1 , 2 , 3 , 4 26 treatment discontinuation . As study first Japanese phase II study product administer combination ATG/CsA subject naive moderate severe AA , subject number study determine 10 base feasibility survey .</brief_summary>
	<brief_title>Eltrombopag Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A Naive Aplastic Anemia ( AA ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Japanese subject age &gt; =18 &lt; 71 year time inform consent . Note : subject age &gt; =71 &lt; 75 may eligible clinically indicate discretion investigator mutual agreement GSK medical monitor . Diagnosed moderate severe AA accord diagnostic criterion AA . The severity classification : Stage I Mild Other stage ; Stage II Moderate At least two follow condition meet : Reticulocyte &lt; 60,000/microliter , Neutrophil &lt; 1,000/microliter , Platelet &lt; 50,000/microliter ; Stage III Moderately severe At least two follow condition meet regular red blood cell transfusion ( need transfusion &gt; =2 unit per month ) require : Reticulocyte &lt; 60,000/microliter , Neutrophil &lt; 1,000/microliter , Platelet &lt; 50,000/microliter ; Stage IV Severe At least two follow condition meet : Reticulocyte &lt; 20,000/microliter , Neutrophil &lt; 500/microliter , Platelet &lt; 20,000/microliter ; Stage V Very severe At least one follow condition meet addition neutrophil &lt; 200/microliter : Reticulocyte &lt; 20,000/microliter , Platelet &lt; 20,000/microliter . Subjects consider indication treatment rabbit ATG CsA . Adequate baseline organ function define follow criterion : Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &lt; =3 × local upper limit normal ( ULN ) Creatinine , total bilirubin , alkaline phosphatase ( ALP ) &lt; 1.5 × local ULN ( total bilirubin &lt; 2.5 × local ULN Gilbert 's Syndrome ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 0 1 Subjects QTcF &lt; 450 millisecond ( msec ) QTcF &lt; 480 msec branch block : QTc QT interval correct Fridericia formula ( QTcF ) , machine , manual overread . QTcF base single average QTc value triplicate ECG . Subjects able understand comply protocol requirement instruction . Subjects sign date informed consent . Subjects meet one follow condition : Male subject female partner childbearing potential must either prior vasectomy agree use acceptable method contraception time enrollment study 16 week last dose eltrombopag ( base upon lifecycle sperm ) . Female subject nonchildbearing potential ( physiologically unable become pregnant ) define : Premenopausal woman document bilateral oophorectomy , bilateral tubal ligation , hysterectomy ; postmenopausal woman least 12 month natural amenorrhea [ uncertain , postmenopausal state confirm hematology result follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit ( mIU ) /milliliter ( mL ) estradiol &lt; 40 picogram ( pg ) /mL ( &lt; 140 picomoles ( pmol ) /L ) ] . Female subject childbearing potential : Defined meeting definition nonchildbearing potential . Female subject childbearing potential must negative serum human chorionic gonadotropin ( hCG ) urine pregnancy test within 7 day prior first dose ATG/CsA . It recommend pregnancy test perform close possible first dose ATG/CsA . Female subject positive pregnancy test must exclude study . Subjects negative pregnancy test must use acceptable contraception include abstinence pregnancy test . Subjects must agree use acceptable contraception include abstinence 14 day prior first dose ATG/CsA 28 day last dose eltrombopag . Diagnosis congenital AA ( e.g . Fanconi anemia Dyskeratosis congenital ) . Subjects sibling donor matched human leukocyte antigen ( HLA ) underwent hematopoietic stem cell transplantation ( HSCT ) previously . However , subject may enrol HSCT indicate , subject want undergo HSCT . Subjects abnormal chromosome ( monosomy 7 detected fluorescence situ hybridization ( FISH ) , aberration detect Gband stain ) . Note : Subjects abnormal chromosome adopt clone definition An International System Human Cytogenetic Nomenclature ( ISCN ) may enrol consult medical monitor . Previous ATG/ALGbased immunosuppressive therapy steroid pulse therapy AA . Treatment CsA within 6 month administration ATG . Subjects paroxysmal nocturnal hemoglobinuria ( PNH ) clone size granulocyte &gt; 50 % flow cytometric analysis . Preexisting cardiac disease ( congestive heart failure New York Heart Association ( NYHA ) Grade II/III/IV ) , arrhythmias know involve risk thromboembolic event ( e.g . atrial fibrillation ) Past history thromboembolic event ( include antiphospholipid antibody syndrome ) current use anticoagulant . Subjects past current malignancy . Note : Subjects history completely resect malignant tumor diseasefree 5 year eligible . Subjects test positive hepatitis B surface ( HBs ) antigen , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody screen . Infection adequately respond appropriate therapy . Subject liver cirrhosis Subjects clinically significant severe cardiac , renal , hepatic medical condition . Pregnant woman ( positive serum urine pregnancy test within 7 day prior first dose ATG/CsA lactate woman ) Note : Female subject lactate eligible participate discontinue nurse prior first dose ATG/CsA refrain nurse 5 day completion treatment eltrombopag . Known hypersensitivity , intolerance allergy rabbit ATG , cyclosporine A , eltrombopag excipients . Current alcohol drug abuse . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) proceed first dose ATG/CsA . Subjects candidate ATG . Subjects candidate CsA . History treatment eltrombopag , romiplostim thrombopoietinreceptor ( TPOR ) agonists .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Eltrombopag</keyword>
	<keyword>rabbit anti-thymocyte globulin</keyword>
	<keyword>additive effect</keyword>
	<keyword>cyclosporine A</keyword>
</DOC>